Market Cap (In USD)
10.24 Million
Revenue (In USD)
-
Net Income (In USD)
-2.08 Million
Avg. Volume
135.63 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0303-0.2045
- PE
- -
- EPS
- -
- Beta Value
- -3.32
- ISIN
- US63108Q1013
- CUSIP
- 63108Q101
- CIK
- 1622057
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Sean Carrick
- Employee Count
- -
- Website
- https://www.nascentbiotech.com
- Ipo Date
- 2009-12-03
- Details
- Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.
More Stocks
-
LABLabo Print S.A.
LAB
-
3419
-
6904
-
TOY
-
601579
-
600903
-
AAPT
-
MHM